Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Review on the Reversal of the Old and New Anticoagulants

A Review on the Reversal of the Old and New Anticoagulants Article: AENJ-D-16-00035 Date: October 24, 2016 Time: 21:44 EARN CE CREDIT ONLINE Go to http://www.nursingcenter.com/CE/AENJ and receive a certificate within minutes. CE Test A Review on the Reversal of the Old and New Anticoagulants Test Instructions Registration deadline is December 31, 2018. approved provider of continuing nursing education by Read the article. The test for this CE activity can only be the District of Columbia, Georgia, and Florida CE Broker taken online at http://www.nursingcenter.com/CE/AENJ. #50-1223. Your certificate is valid in all states. Provider Accreditation Tests can no longer be mailed or faxed. The ANCC’s accreditation status of Lippincott Lippincott Williams & Wilkins, the publisher of Advanced You will need to create (its free!) and login to your Williams & Wilkins Department of Continuing Educa- Emergency Nursing Journal, will award 3.0 contact hours personal CE Planner account before taking online tests. tion refers only to its continuing nursing educational for this continuing nursing education activity. This activity Your planner will keep track of all your Lippincott Williams activities and does not imply Commission on Accred- has been assigned 3.0 pharmacology credits. & Wilkins online CE activities for you. itation approval or endorsement of any commercial Lippincott Williams & Wilkins is accredited as There is only one correct answer for each question. product. a provider of continuing nursing education by the A passing score for this test is 13 correct answers. If American Nurses Credentialing Center’s Commission on you pass, you can print your certificate of earned contact Disclosure Statement Accreditation. hours and access the answer key. If you fail, you have All authors and planners have no financial relationships This activity is also provider approved by the the option of taking the test again at no additional cost. related to this article to disclose. California Board of Registered Nursing, Provider Num- For questions, contact Lippincott Williams & Wilkins: ber CEP 11749 for 3.0 contact hours. LWW is also an 1-800-787-8985. CE TEST QUESTIONS Purpose: To provide information regarding anticoag- 6. A bridge using enoxaparin and war- 13. What should be given along with ulants and their reversal agents. farin is continued for a minimum of FEIBA? Learning Objectives/Outcomes: After com- a. 2 days. a. protamine pleting this continuing education activity, you will be b. 3 days. b. vitamin K able to: c. 5 days. c. four-factor prothrombin complex concentrate 1. Recognize side effects and considerations related to 7. Which of the following lab values (4F-PCC) (human) would most likely aid in enoxaparin 14. FEIBA would be expected to most ef- new oral anticoagulants. 2. Recognize side effects and considerations related to dosing? fectively reverse the effects of warfarin and heparin. a. hemoglobin a. dabigatran. 3. Identify selection, dosage, administration, and side b. liver function tests b. warfarin. effects of reversal agents. c. creatinine clearance c. enoxaparin. 8. Compared with warfarin, the stroke 15. 4F-PCC (Kcentra) has been approved 1. Compared with warfarin, the new an- risk with apixaban administration is for reversing the effects of ticoagulants a. similar. a. rivaroxaban. a. have more drug–drug interactions. b. lower. b. dabigatran. b. exhibit greater variability between patients. c. higher. c. warfarin. c. are difficult to monitor efficacy. 9. Which of the following is the cor- 16. The maximum rate for a Kcentra infu- 2. The mortality and morbidity of pa- nerstone for treatment of critical sion is about tients taking anticoagulants is re- warfarin-related bleeding? a. 90 units/min. portedtobeashighas a. platelets b. 170 units/min. a. 21%. b. vitamin K c. 210 units/min. b. 54%. c. freshfrozenplasma 17. Which of the following is the least c. 66%. 10. What dose of vitamin K for revers- common side effect of Kcentra? 3. Because warfarin inhibits protein C ing the effects of warfarin may be re- a. hypotension and S production, quired for life-threatening bleeding? b. nausea and vomiting a. it should be started in combination with a par- a. 2.5 mg c. deep vein thrombosis enteral anticoagulant. b. 7.5 mg 18. Adverse events from idarucizumab b. it normally takes 7–14 days for their degrada- c. 12.5 mg (Praxbind) may be more likely in pa- tion. 11. Protamine partially reverses the ef- tients with an intolerance to c. patients taking amiodarone may require in- fects of a. fructose. creased warfarin doses. a. enoxaparin. b. propylene. 4. Which of the following concomitant b. unfractionated heparin. c. cellulose. drugs should justify lowering the war- c. warfarin. farin dose? 12. Activated prothrombin complex con- a. rifampin centrate (FEIBA) for anticoagulation b. metronidazole reversal is dosed on the basis of c. carbamazepine a. severity of bleeding. 5. Compared with warfarin, the new an- b. patient weight. ticoagulants are associated with a c. creatinine clearance. higher occurrence of a. gastrointestinal bleeding. b. intracranial hemorrhaging. c. thrombus formation. E4 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advanced Emergency Nursing Journal Wolters Kluwer Health

A Review on the Reversal of the Old and New Anticoagulants

Advanced Emergency Nursing Journal , Volume 38 (4) – Oct 1, 2016

Loading next page...
 
/lp/wolters-kluwer-health/a-review-on-the-reversal-of-the-old-and-new-anticoagulants-J4P1lFIJ3M

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1931-4485
eISSN
1931-4493
DOI
10.1097/TME.0000000000000129
pmid
27792076
Publisher site
See Article on Publisher Site

Abstract

Article: AENJ-D-16-00035 Date: October 24, 2016 Time: 21:44 EARN CE CREDIT ONLINE Go to http://www.nursingcenter.com/CE/AENJ and receive a certificate within minutes. CE Test A Review on the Reversal of the Old and New Anticoagulants Test Instructions Registration deadline is December 31, 2018. approved provider of continuing nursing education by Read the article. The test for this CE activity can only be the District of Columbia, Georgia, and Florida CE Broker taken online at http://www.nursingcenter.com/CE/AENJ. #50-1223. Your certificate is valid in all states. Provider Accreditation Tests can no longer be mailed or faxed. The ANCC’s accreditation status of Lippincott Lippincott Williams & Wilkins, the publisher of Advanced You will need to create (its free!) and login to your Williams & Wilkins Department of Continuing Educa- Emergency Nursing Journal, will award 3.0 contact hours personal CE Planner account before taking online tests. tion refers only to its continuing nursing educational for this continuing nursing education activity. This activity Your planner will keep track of all your Lippincott Williams activities and does not imply Commission on Accred- has been assigned 3.0 pharmacology credits. & Wilkins online CE activities for you. itation approval or endorsement of any commercial Lippincott Williams & Wilkins is accredited as There is only one correct answer for each question. product. a provider of continuing nursing education by the A passing score for this test is 13 correct answers. If American Nurses Credentialing Center’s Commission on you pass, you can print your certificate of earned contact Disclosure Statement Accreditation. hours and access the answer key. If you fail, you have All authors and planners have no financial relationships This activity is also provider approved by the the option of taking the test again at no additional cost. related to this article to disclose. California Board of Registered Nursing, Provider Num- For questions, contact Lippincott Williams & Wilkins: ber CEP 11749 for 3.0 contact hours. LWW is also an 1-800-787-8985. CE TEST QUESTIONS Purpose: To provide information regarding anticoag- 6. A bridge using enoxaparin and war- 13. What should be given along with ulants and their reversal agents. farin is continued for a minimum of FEIBA? Learning Objectives/Outcomes: After com- a. 2 days. a. protamine pleting this continuing education activity, you will be b. 3 days. b. vitamin K able to: c. 5 days. c. four-factor prothrombin complex concentrate 1. Recognize side effects and considerations related to 7. Which of the following lab values (4F-PCC) (human) would most likely aid in enoxaparin 14. FEIBA would be expected to most ef- new oral anticoagulants. 2. Recognize side effects and considerations related to dosing? fectively reverse the effects of warfarin and heparin. a. hemoglobin a. dabigatran. 3. Identify selection, dosage, administration, and side b. liver function tests b. warfarin. effects of reversal agents. c. creatinine clearance c. enoxaparin. 8. Compared with warfarin, the stroke 15. 4F-PCC (Kcentra) has been approved 1. Compared with warfarin, the new an- risk with apixaban administration is for reversing the effects of ticoagulants a. similar. a. rivaroxaban. a. have more drug–drug interactions. b. lower. b. dabigatran. b. exhibit greater variability between patients. c. higher. c. warfarin. c. are difficult to monitor efficacy. 9. Which of the following is the cor- 16. The maximum rate for a Kcentra infu- 2. The mortality and morbidity of pa- nerstone for treatment of critical sion is about tients taking anticoagulants is re- warfarin-related bleeding? a. 90 units/min. portedtobeashighas a. platelets b. 170 units/min. a. 21%. b. vitamin K c. 210 units/min. b. 54%. c. freshfrozenplasma 17. Which of the following is the least c. 66%. 10. What dose of vitamin K for revers- common side effect of Kcentra? 3. Because warfarin inhibits protein C ing the effects of warfarin may be re- a. hypotension and S production, quired for life-threatening bleeding? b. nausea and vomiting a. it should be started in combination with a par- a. 2.5 mg c. deep vein thrombosis enteral anticoagulant. b. 7.5 mg 18. Adverse events from idarucizumab b. it normally takes 7–14 days for their degrada- c. 12.5 mg (Praxbind) may be more likely in pa- tion. 11. Protamine partially reverses the ef- tients with an intolerance to c. patients taking amiodarone may require in- fects of a. fructose. creased warfarin doses. a. enoxaparin. b. propylene. 4. Which of the following concomitant b. unfractionated heparin. c. cellulose. drugs should justify lowering the war- c. warfarin. farin dose? 12. Activated prothrombin complex con- a. rifampin centrate (FEIBA) for anticoagulation b. metronidazole reversal is dosed on the basis of c. carbamazepine a. severity of bleeding. 5. Compared with warfarin, the new an- b. patient weight. ticoagulants are associated with a c. creatinine clearance. higher occurrence of a. gastrointestinal bleeding. b. intracranial hemorrhaging. c. thrombus formation. E4

Journal

Advanced Emergency Nursing JournalWolters Kluwer Health

Published: Oct 1, 2016

There are no references for this article.